Stratification test for ADT effectiveness

[ron_bucher]

As someone who has had the awful experience of ADT side effects, I give this tool a standing ovation:

artera.ai/arteraai-prostate...

Just approved for Medicare coverage, and just a matter of time before California and New York join the other 48 states in approving it.

[Researcher50]

Would have loved to have had this tool at diagnosis. At that time, RO just stated no need for ADT with T1c, so who knows if he would have benefited and not have current rising PSA? OTOH, it would have been great to have some sort of testing to back up the RO's opinion that ADT was unnecessary since ADT +RT seems to be pretty SOC these days.

[maley2711]

Thanks....apparently for intermediate only, and they don't mention NCCN favorable or unfavorable risk group......perhaps that explains their success with the test???? How much are they actually improving the risk classification with the use of biopsy slides??? Just asking!!! I like to think the FDA and Medicare aren't susceptible to being duped????

[Grandpa4]

so just to clarify. This is just in the setting of radiation at the point where there are no know metastasis outside the pelvis. It is not predicting the value at other times in your course because when it comes back after radiation the value is nearly 100%. What the data are saying is people with their biomarker (probably bad histologies) have very low chances of success and anti androgens don’t them help. The response to radiation is pretty bad in this group.

[ron_bucher]

Here is better information: urotoday.com/conference-hig...